New combo therapy for diabetes and obesity tested – but study pulled
NCT ID NCT07172867
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study aimed to see if adding a new drug called ofirnoflast to semaglutide helps control blood sugar and promote weight loss better than semaglutide alone in overweight or obese adults with type 2 diabetes. Participants would have taken the drugs for 12 weeks. However, the study was withdrawn before enrolling anyone, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Abu Dhabi
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Conditions
Explore the condition pages connected to this study.